Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET
Company Participants
Andrew Faughnan - Vice President, Investor Relations
Bradley Campbell - President and CEO
Sebastien Martel - Chief Business Officer
Dr. Jeff Castelli - Chief Development Officer
Simon Harford - Chief Financial Officer
Dr. Mitchell Goldman - Chief Medical Officer
Ellen Rosenberg - Chief Legal Officer
Conference Call Participants
Tazeen Ahmad - BofA Securities
Ellie Merle - UBS
Anupam Rama - JPM
Ritu Baral - TD Cowen
Michael Riad - Morgan Stanley
Dae Gon Ha - Stifel
Shrunatra Mishra - Goldman Sachs
Rick Miller - Cantor Fitzgerald
Operator
Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session, and instructions will follow at that time. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Vice President of Investor Relations. You may begin.
Andrew Faughnan
Thank you. Good morning. And thank you for joining our conference call to discuss Amicus Therapeutic’s second quarter 2024 financial results and corporate highlights. Leading today’s call, we have Bradley Campbell, President and Chief Executive Officer; Sebastien Martel, Chief Business Officer; Dr. Jeff Castelli, Chief Development Officer; and Simon Harford, Chief Financial Officer. Joining for Q&A is Dr. Mitchell Goldman, Chief Medical Officer; and Ellen Rosenberg, Chief Legal Officer.
As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Security Litigation Reform Act of 1995 relating to our business, as well as our plans and prospects.
Our forward-looking statements should not be regarded as representation by us that any of our plans would be achieved. Any or all of the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties.
You are cautioned not to place undue reliance on any forward-looking statements which speak only to the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this presentation and conference call to reflect events or circumstances after the date hereof.
For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and risk factor sections of our annual report on Form 10-K for the year-ended December 31, 2023 and the quarterly report on Form 10-Q for the quarter ended June 30, 2024 to be filed with the Securities and Exchange Commission today.